Skip to content

Clinical trials

Phase 1/2 Primary Myelofibrosis trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Primary Myelofibrosis Phase: Phase 1/2 Clear all

65 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20021
20032
20042
20052
20061
20071
20086
20094
20102
20112
20134
20141
20153
20165
20171
20194
20203
20214
20223
20231
20243
20254
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed31
Recruiting11
Terminated10
Withdrawn4
Unknown status4
Active, not recruiting3
Suspended1
Not yet recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
M.D. Anderson Cancer Center6
Incyte Corporation5
Bristol-Myers Squibb3
Fred Hutchinson Cancer Center3
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.2
John Mascarenhas2
Kartos Therapeutics, Inc.2
Novartis Pharmaceuticals2
Ronald Hoffman2
S*BIO2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Primary Myelofibrosis65
Myeloproliferative Disorders29
Myelodysplastic Syndromes23
Leukemia, Myeloid, Acute21
Polycythemia Vera21
Thrombocythemia, Essential19
Leukemia17
Lymphoma13
Precursor Cell Lymphoblastic Leukemia-Lymphoma13
Leukemia, Myelomonocytic, Chronic12

Trials

Showing 76 to 65 of 65. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.